Updated:
CBD Life Sciences
CBD Life Sciences Inc. develops hemp-derived CBD consumer products in the US, operating a direct-to-consumer model after the 2018 Farm Bill.
CBD Life Sciences
CBD Life Sciences Inc. is a US-based company formed to develop and sell products derived from industrial hemp, primarily focusing on cannabidiol (CBD) and other non-psychoactive cannabinoids. The company's public identity emerged in the wake of the 2018 Farm Bill, which federally legalized hemp, creating a flood of new market entrants competing for early brand recognition in a regulatory gray area overseen by the FDA. The firm's strategy hinges on vertical integration, aiming to control a product's path from raw material extraction through to white-label and direct-to-consumer retail fulfillment. The company's deployment model centers on building a portfolio of consumer brands across multiple delivery formats, including oils, capsules, gummies, and topical creams. Its stated geographic footprint targets the US domestic market, operating a direct-to-consumer e-commerce platform while pursuing placement in brick-and-mortar retail channels like smoke shops, wellness boutiques, and convenience stores. The strategy reflects a standard playbook in the cannabinoid space: prioritizing top-line revenue through digital marketing spend and wholesale distribution agreements rather than in-house drug development, which is typical of more heavily capitalized cannabis biotech firms. As a venture on the OTC market, the firm faces a structural challenge of scale, relying on equity financing to fund operations in a capital-constrained micro-cap sector. The business model does not involve investing in external startups or running a fund structure; rather, it functions as an operating company where investor capital directly fuels inventory buildup and marketing. The management team has historically communicated its growth narrative through press releases, a standard practice for OTC-listed companies seeking to maintain visibility among retail investors and potential acquisition partners. A differentiating factor for CBD Life Sciences Inc. versus purely private competitors is its public listing, which, while providing access to retail capital markets, also subjects it to the volatility and disclosure requirements of the OTC tier. This creates a dual mandate: managing the operational capital needs of a protein-poor consumer product startup while also managing public market investor relations. The company's fate is tied to its ability to convert a broadly available botanical commodity into a branded, shelf-stable margin before a wave of market consolidation arrives.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What specific consumer products does CBD Life Sciences develop?
The company focuses on a standard cannabinoid wellness line that includes CBD oil tinctures, topical creams, gummies, and capsules. These products are marketed for general wellness, leveraging the broad consumer interest in CBD that followed the 2018 US Farm Bill. The formulations are derived from industrial hemp and are sold as dietary supplements, a category that operates under specific FDA enforcement discretion as the agency has not yet established a comprehensive regulatory pathway for CBD as a food additive or supplement.
How does the 2018 Farm Bill affect the company's operations?
The Agriculture Improvement Act of 2018 federally descheduled hemp and its derivatives, including CBD, provided they contain no more than 0.3 percent delta-9 THC. This legislation created the legal framework for companies like CBD Life Sciences to legally cultivate, process, and ship industrial hemp products across state lines. Prior to this, such activities were largely in a legal gray area, and the bill's passage is directly responsible for the commercial viability of the company's core product lines.
Does CBD Life Sciences conduct clinical trials on its products?
There is no public evidence that the company sponsors FDA-regulated clinical trials for drug development, which would be a far more capital-intensive path typical of pharmaceutical cannabinoid companies like those developing Epidiolex. Instead, the firm operates in the consumer packaged goods and dietary supplement space, where products are marketed with structure-function claims that do not require pre-market FDA approval, though they are subject to labeling and safety requirements.
How does the company distribute its products?
The company follows a dual distribution strategy common to the hemp-derived CBD sector: a direct-to-consumer e-commerce platform and a wholesale distribution network. The DTC channel aims to capture higher margins by selling via its own websites, while the wholesale push targets physical retail partners, including wellness boutiques, smoke shops, and convenience stores, though exact partnership names are not a matter of public record.
What is the regulatory risk facing the company's business model?
The primary regulatory risk is the FDA's ongoing refusal to formally approve CBD as a dietary supplement or food additive, citing insufficient safety data for long-term ingestion. Until the agency creates a legal pathway for such use, or Congress mandates one, companies like CBD Life Sciences operate at the FDA's enforcement discretion, carrying the risk of warning letters, product seizures, or forced reformulation that could disrupt revenue and devalue branded inventory.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: